FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

ABSTRACT:

Background

Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to stratify patients based on mutations in relevant oncogenes. Patients with non-muscle-invasive bladder cancer (NMI-BC) have excellent survival, however two-thirds develop recurrences. Tumor specific mutations can be used to detect recurrences in urine assays, presenting a more patient-friendly diagnostic procedure than cystoscopy.

Methodology/principal findings

To address these issues, we developed a mutation assay for the simultaneous detection of 19 possible mutations in the HRAS, K

SUBMITTER: Kompier LC 

PROVIDER: S-EPMC2972209 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature